Net profit stood at ₹520 crore in Q1FY27, compared with ₹664 crore in the year-ago quarter.
Revenue from operations, however, increased 11% YoY to ₹3,740 crore from ₹3,371 crore. India sales grew 10.3% year-on-year to ₹2,497.8 crore, while international sales rose 16% to ₹1,222.3 crore.
EBITDA increased 16.2% YoY to ₹766.6 crore from ₹660 crore. EBITDA margin improved to 20.5% from 19.6% a year earlier.
Alkem Laboratories Managing Director Sandeep Singh said the company had started FY27 on a steady note, with healthy growth across its India and international businesses.
He said the India business continued to outperform the market, while growth in non-US international markets remained encouraging. However, he flagged the need to improve execution, address operational and regulatory priorities and ensure more consistent performance across the company’s businesses.
The company is also investing in R&D, MedTech and Biotech as it looks to build new growth opportunities while strengthening its core businesses.
